Lupus Research Institute Encouraged by Phase 2 Trial Results of Experimental Drug Epratuzumab

The Lupus Research Institute (LRI) and its National Coalition of state and local organizations congratulate Immunomedics and UCB on the successful results of the Phase 2b clinical trial of epratuzumab for people with systemic lupus.

“It is heartening to see success in lupus trials and to see innovative companies investing in new research to combat this devastating disease,” said LRI President, Margaret G. Dowd. “Lupus is full of surprises and this is a welcome outcome. Each successful trial brings us closer to a cure and we look forward to the results of the next trial phase.”

In the mid-stage trial, there was a favorable difference in reduction of lupus symptoms between the placebo group and at least one treatment group detected early (12 weeks) after the start of treatment at different dosage levels.